Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monday broker round-up UPDATE

Mon, 28th Jul 2014 11:06

African Barrick Gold: UBS ups target price from 260p to 290p and maintains a buy recommendation. Deutsche Bank cuts target price from 300p to 280p and reiterates a buy recommendation.Anglo American: UBS downgrades from buy to neutral with a target price of 1700p.Barclays: Nomura cuts target price from 300p to 275p maintaining a buy recommendation.BSkyB: Nomura ups target price from 870p to 900p and upgrades from reduce to neutral.Cranswick: Numis downgrades from add to hold with a target price of 1326p.GlaxoSmithKline: UBS reduces target price from 1500p to 1380p retaining its sell recommendation.Jardine Lloyd Thompson: Panmure Gordon increases target price from 925p to 1050p and upgrades from sell to hold.Lonmin: Deutsche Bank ups target price from 320p to 350p keeping a buy recommendation. Investec moves target price from 239p to 248p and upgrades from sell to hold.Mitchells & Butlers: Deutsche Bank cuts target price from 620p to 590p leaving its buy recommendation unchanged.Pace: Canaccord Genuity raises target price from 457p to 475p and retains a buy recommendation.Pearson: Numis shifts target price from 1189p to 1194p keeping a hold recommendation. Berenberg increases target price from 1022p to 1160p and reiterates a hold recommendation.Reckitt Benckiser: Canaccord Genuity raises target price from 4100p to 4500p, but still recommends selling.Royal Bank of Scotland: UBS ups target price from 320p to 378p upgrading from sell to neutral. Credit Suisse raises target price from 280p to 310p staying with its underperform rating. Deutsche Bank moves target price from 325p to 335p and keeps a hold recommendation. Numis raises target price from 300p to 378p and retains a hold recommendation.SOCO International: Jefferies takes target price from 400p to 480p upgrading from hold to buy.Spectris: Canaccord Genuity places both its target price (prev.: 2700p) and its buy recommendation under review.Trinity Mirror: Numis moves target price from 280p to 294p maintaining a buy recommendation.
More News
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 17:10

Miners, personal goods stocks drag FTSE 100 to two-week low

Burberry slips on rating downgrade

*

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 12:10

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.